Patent intelligence · US
US 11707457
IRAK degraders and uses thereof
IRAK degraders and uses thereof
Patent details — US 11707457
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 25, 2023
- Expiration
- Jul 20, 2043
- Applicant
- Kymera Therapeutics, Inc.
- Claims
- 30
- CPC classes
- A61K, A61K31/4545, A61K31/4725, A61K31/497
Quick answer
US 11707457 (IRAK degraders and uses thereof) is held by Kymera Therapeutics, Inc.. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Kymera Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/4545, A61K31/4725, A61K31/497, A61K31/501, A61K31/506
More from Kymera Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12258341
IRAK degraders and uses thereof
granted -
US 12187744
IRAK4 degraders and synthesis thereof
granted -
US 12171768
IRAK4 degraders and uses thereof
granted -
US 12168057
IRAK degraders and uses thereof
granted -
US 12150995
IRAK degraders and uses thereof
granted -
US 12097261
CDK2 degraders and uses thereof
granted -
US 12091411
IRAK degraders and uses thereof
granted -
US 12077555
STAT degraders and uses thereof
granted
Frequently asked questions
What is US patent 11707457?
US 11707457 (IRAK degraders and uses thereof) is held by Kymera Therapeutics, Inc.. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11707457?
Kymera Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 29 pharmaceutical patents for this assignee.
When does US 11707457 expire?
Our index shows an expiration date of Jul 20, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.